| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 322 | 2024 | 20988 | 15.530 |
Why?
|
| Antineoplastic Agents, Hormonal | 40 | 2024 | 1520 | 6.320 |
Why?
|
| Pregnancy Complications, Neoplastic | 17 | 2024 | 258 | 4.580 |
Why?
|
| Mastectomy | 32 | 2024 | 1817 | 4.510 |
Why?
|
| Chemotherapy, Adjuvant | 70 | 2024 | 3514 | 3.850 |
Why?
|
| Ovary | 20 | 2022 | 959 | 3.780 |
Why?
|
| Premenopause | 25 | 2022 | 1038 | 3.340 |
Why?
|
| Fertility | 21 | 2024 | 769 | 3.200 |
Why?
|
| Survivors | 42 | 2024 | 2373 | 2.960 |
Why?
|
| Receptor, erbB-2 | 39 | 2024 | 2553 | 2.800 |
Why?
|
| Tamoxifen | 21 | 2024 | 965 | 2.740 |
Why?
|
| Decision Making | 25 | 2023 | 3919 | 2.580 |
Why?
|
| Quality of Life | 54 | 2024 | 13359 | 2.560 |
Why?
|
| Amenorrhea | 15 | 2021 | 483 | 2.450 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 14 | 2024 | 926 | 2.410 |
Why?
|
| Infertility, Female | 12 | 2019 | 760 | 2.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 47 | 2024 | 11735 | 2.130 |
Why?
|
| Antineoplastic Agents | 41 | 2022 | 13635 | 2.040 |
Why?
|
| Anxiety | 23 | 2022 | 4573 | 1.980 |
Why?
|
| Female | 362 | 2024 | 392203 | 1.940 |
Why?
|
| Neoplasms | 42 | 2024 | 22131 | 1.900 |
Why?
|
| Carcinoma, Ductal, Breast | 12 | 2023 | 1084 | 1.880 |
Why?
|
| Receptors, Estrogen | 25 | 2024 | 2208 | 1.790 |
Why?
|
| Adult | 215 | 2024 | 220995 | 1.670 |
Why?
|
| Primary Ovarian Insufficiency | 9 | 2021 | 107 | 1.670 |
Why?
|
| Mastectomy, Segmental | 16 | 2024 | 955 | 1.650 |
Why?
|
| Neoplasm Recurrence, Local | 33 | 2024 | 9277 | 1.650 |
Why?
|
| Aromatase Inhibitors | 10 | 2024 | 513 | 1.600 |
Why?
|
| Medication Adherence | 13 | 2024 | 2175 | 1.580 |
Why?
|
| Neoadjuvant Therapy | 16 | 2024 | 2827 | 1.520 |
Why?
|
| Carcinoma in Situ | 4 | 2022 | 791 | 1.510 |
Why?
|
| Humans | 399 | 2024 | 760740 | 1.440 |
Why?
|
| Sexual Partners | 4 | 2023 | 800 | 1.330 |
Why?
|
| Gonadotropin-Releasing Hormone | 11 | 2018 | 1148 | 1.330 |
Why?
|
| BRCA2 Protein | 8 | 2024 | 797 | 1.300 |
Why?
|
| Sexual Dysfunction, Physiological | 4 | 2023 | 361 | 1.290 |
Why?
|
| Receptors, Progesterone | 13 | 2024 | 1129 | 1.230 |
Why?
|
| Clinical Trials as Topic | 22 | 2022 | 7995 | 1.150 |
Why?
|
| Neoplasms, Second Primary | 3 | 2024 | 1051 | 1.140 |
Why?
|
| Neoplasm Staging | 36 | 2024 | 11118 | 1.130 |
Why?
|
| Prospective Studies | 57 | 2024 | 54364 | 1.120 |
Why?
|
| Breast Neoplasms, Male | 6 | 2019 | 212 | 1.120 |
Why?
|
| Paclitaxel | 17 | 2024 | 1730 | 1.110 |
Why?
|
| Young Adult | 68 | 2024 | 59191 | 1.110 |
Why?
|
| Patient Compliance | 8 | 2014 | 2688 | 1.080 |
Why?
|
| BRCA1 Protein | 9 | 2024 | 1149 | 1.080 |
Why?
|
| Infertility | 7 | 2021 | 654 | 1.060 |
Why?
|
| Pregnancy | 50 | 2024 | 29869 | 1.050 |
Why?
|
| Age Factors | 39 | 2024 | 18381 | 0.990 |
Why?
|
| Medical Oncology | 19 | 2023 | 2317 | 0.950 |
Why?
|
| Adaptation, Psychological | 8 | 2023 | 2632 | 0.920 |
Why?
|
| Depression | 20 | 2024 | 8132 | 0.910 |
Why?
|
| Fatigue | 13 | 2024 | 1550 | 0.890 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2019 | 4010 | 0.890 |
Why?
|
| Menopause | 8 | 2024 | 1645 | 0.880 |
Why?
|
| Middle Aged | 139 | 2024 | 220603 | 0.830 |
Why?
|
| Body Image | 5 | 2020 | 639 | 0.830 |
Why?
|
| Nitriles | 6 | 2024 | 971 | 0.820 |
Why?
|
| Ovariectomy | 5 | 2024 | 613 | 0.810 |
Why?
|
| Attitude to Health | 4 | 2019 | 2025 | 0.800 |
Why?
|
| Hormones | 4 | 2022 | 869 | 0.780 |
Why?
|
| Triazoles | 5 | 2024 | 903 | 0.780 |
Why?
|
| Genes, BRCA2 | 8 | 2024 | 590 | 0.770 |
Why?
|
| Patient Participation | 8 | 2019 | 1443 | 0.770 |
Why?
|
| Disease-Free Survival | 22 | 2024 | 6807 | 0.770 |
Why?
|
| Patient Preference | 3 | 2018 | 925 | 0.750 |
Why?
|
| Perception | 5 | 2015 | 1199 | 0.750 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 6 | 2023 | 1081 | 0.730 |
Why?
|
| Genetic Testing | 8 | 2022 | 3533 | 0.730 |
Why?
|
| Genes, BRCA1 | 7 | 2024 | 753 | 0.700 |
Why?
|
| Oxazoles | 1 | 2021 | 199 | 0.700 |
Why?
|
| Cryopreservation | 8 | 2024 | 728 | 0.670 |
Why?
|
| Pyridines | 5 | 2024 | 2875 | 0.670 |
Why?
|
| Sexual Behavior | 5 | 2023 | 2187 | 0.660 |
Why?
|
| Disclosure | 4 | 2009 | 747 | 0.660 |
Why?
|
| Social Support | 8 | 2024 | 2174 | 0.650 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2021 | 857 | 0.650 |
Why?
|
| Mammography | 6 | 2023 | 2430 | 0.650 |
Why?
|
| Research Subjects | 2 | 2015 | 249 | 0.630 |
Why?
|
| Patient Education as Topic | 16 | 2024 | 2315 | 0.630 |
Why?
|
| Pregnancy Rate | 4 | 2020 | 648 | 0.610 |
Why?
|
| Prognosis | 28 | 2024 | 29601 | 0.610 |
Why?
|
| Socioeconomic Factors | 12 | 2021 | 7805 | 0.600 |
Why?
|
| Patient Satisfaction | 12 | 2021 | 3451 | 0.600 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 517 | 0.580 |
Why?
|
| Communication | 10 | 2022 | 3851 | 0.580 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2019 | 192 | 0.570 |
Why?
|
| Hot Flashes | 8 | 2024 | 330 | 0.560 |
Why?
|
| Reproductive History | 2 | 2015 | 210 | 0.550 |
Why?
|
| Withholding Treatment | 3 | 2023 | 615 | 0.540 |
Why?
|
| Breast | 9 | 2023 | 1963 | 0.540 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 1590 | 0.540 |
Why?
|
| Aged | 89 | 2024 | 169092 | 0.540 |
Why?
|
| Molecular Targeted Therapy | 5 | 2020 | 2812 | 0.540 |
Why?
|
| Goserelin | 3 | 2019 | 126 | 0.540 |
Why?
|
| Patient Selection | 7 | 2020 | 4237 | 0.530 |
Why?
|
| Parity | 4 | 2015 | 924 | 0.530 |
Why?
|
| Fluorouracil | 7 | 2019 | 1642 | 0.530 |
Why?
|
| Patient Care Planning | 5 | 2019 | 905 | 0.530 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2019 | 645 | 0.520 |
Why?
|
| Exercise Therapy | 3 | 2019 | 929 | 0.520 |
Why?
|
| Oocyte Retrieval | 1 | 2017 | 160 | 0.510 |
Why?
|
| Parenting | 1 | 2022 | 702 | 0.510 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2015 | 58 | 0.510 |
Why?
|
| Combined Modality Therapy | 13 | 2023 | 8516 | 0.500 |
Why?
|
| Carcinoma | 3 | 2021 | 2328 | 0.500 |
Why?
|
| Expert Testimony | 2 | 2017 | 364 | 0.500 |
Why?
|
| Outpatients | 1 | 2023 | 1596 | 0.500 |
Why?
|
| Quinazolines | 2 | 2021 | 1371 | 0.500 |
Why?
|
| Continuity of Patient Care | 6 | 2021 | 1067 | 0.480 |
Why?
|
| United States | 43 | 2024 | 72292 | 0.480 |
Why?
|
| Pregnancy Outcome | 7 | 2024 | 2921 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 16 | 2024 | 10203 | 0.480 |
Why?
|
| Risk Factors | 35 | 2024 | 74128 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 14 | 2024 | 7390 | 0.470 |
Why?
|
| Personal Autonomy | 1 | 2017 | 304 | 0.470 |
Why?
|
| Employment | 3 | 2022 | 1113 | 0.470 |
Why?
|
| Cohort Studies | 27 | 2024 | 41464 | 0.470 |
Why?
|
| Deoxycytidine | 5 | 2012 | 878 | 0.460 |
Why?
|
| Antineoplastic Protocols | 1 | 2014 | 48 | 0.460 |
Why?
|
| Attitude of Health Personnel | 5 | 2018 | 3882 | 0.460 |
Why?
|
| Hematopoiesis | 2 | 2023 | 2049 | 0.460 |
Why?
|
| Oocytes | 3 | 2017 | 1166 | 0.460 |
Why?
|
| Cyclophosphamide | 11 | 2021 | 2218 | 0.460 |
Why?
|
| Physicians | 6 | 2019 | 4583 | 0.450 |
Why?
|
| Standard of Care | 2 | 2015 | 551 | 0.450 |
Why?
|
| Menopause, Premature | 5 | 2021 | 124 | 0.450 |
Why?
|
| Qualitative Research | 3 | 2023 | 3017 | 0.450 |
Why?
|
| Adolescent | 31 | 2024 | 88247 | 0.450 |
Why?
|
| Communication Barriers | 1 | 2017 | 414 | 0.450 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 702 | 0.450 |
Why?
|
| Physician-Patient Relations | 11 | 2019 | 3239 | 0.450 |
Why?
|
| Stress, Psychological | 6 | 2023 | 4488 | 0.450 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2012 | 123 | 0.440 |
Why?
|
| Hormone Replacement Therapy | 2 | 2024 | 751 | 0.440 |
Why?
|
| Risk Assessment | 20 | 2021 | 23974 | 0.430 |
Why?
|
| Treatment Outcome | 40 | 2024 | 64572 | 0.420 |
Why?
|
| Carcinoma, Lobular | 1 | 2017 | 480 | 0.420 |
Why?
|
| Research Design | 7 | 2022 | 6174 | 0.410 |
Why?
|
| Spouses | 1 | 2015 | 283 | 0.410 |
Why?
|
| Women | 1 | 2014 | 224 | 0.400 |
Why?
|
| Patient Advocacy | 2 | 2012 | 360 | 0.400 |
Why?
|
| Health Education | 1 | 2019 | 1049 | 0.400 |
Why?
|
| Brain Neoplasms | 3 | 2024 | 9026 | 0.400 |
Why?
|
| Income | 2 | 2020 | 1870 | 0.390 |
Why?
|
| Inpatients | 1 | 2023 | 2545 | 0.390 |
Why?
|
| Survival Rate | 12 | 2024 | 12719 | 0.390 |
Why?
|
| Obesity | 6 | 2023 | 12934 | 0.380 |
Why?
|
| Delayed Diagnosis | 2 | 2013 | 463 | 0.380 |
Why?
|
| Caregivers | 1 | 2023 | 2241 | 0.370 |
Why?
|
| Models, Organizational | 1 | 2014 | 544 | 0.370 |
Why?
|
| Breast Feeding | 1 | 2019 | 1355 | 0.370 |
Why?
|
| Ovulation Induction | 3 | 2024 | 277 | 0.370 |
Why?
|
| Administration, Oral | 9 | 2024 | 4010 | 0.360 |
Why?
|
| Neoplasm, Residual | 5 | 2024 | 1008 | 0.360 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2013 | 410 | 0.360 |
Why?
|
| Follow-Up Studies | 24 | 2024 | 39062 | 0.350 |
Why?
|
| Live Birth | 3 | 2023 | 510 | 0.340 |
Why?
|
| Rare Diseases | 1 | 2015 | 622 | 0.340 |
Why?
|
| Embryo, Mammalian | 2 | 2015 | 1670 | 0.340 |
Why?
|
| Mediastinal Diseases | 2 | 2000 | 91 | 0.340 |
Why?
|
| Meditation | 2 | 2024 | 251 | 0.340 |
Why?
|
| Drug Administration Schedule | 6 | 2015 | 4845 | 0.330 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2009 | 726 | 0.330 |
Why?
|
| Biomedical Research | 5 | 2019 | 3426 | 0.330 |
Why?
|
| Piperazines | 3 | 2024 | 2521 | 0.330 |
Why?
|
| Aged, 80 and over | 32 | 2024 | 58919 | 0.320 |
Why?
|
| Lymphatic Diseases | 2 | 2000 | 320 | 0.310 |
Why?
|
| Tumor Burden | 5 | 2017 | 1892 | 0.300 |
Why?
|
| Time Factors | 16 | 2024 | 39908 | 0.300 |
Why?
|
| Body Mass Index | 8 | 2023 | 12942 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2023 | 17878 | 0.300 |
Why?
|
| Germ-Line Mutation | 6 | 2024 | 1852 | 0.300 |
Why?
|
| Exercise | 9 | 2023 | 5886 | 0.290 |
Why?
|
| Logistic Models | 10 | 2018 | 13248 | 0.290 |
Why?
|
| Educational Status | 5 | 2019 | 2509 | 0.290 |
Why?
|
| Ovarian Follicle | 1 | 2009 | 244 | 0.290 |
Why?
|
| Phytoestrogens | 1 | 2007 | 59 | 0.290 |
Why?
|
| Interpersonal Relations | 1 | 2015 | 1438 | 0.290 |
Why?
|
| Overweight | 3 | 2022 | 2417 | 0.290 |
Why?
|
| Germ Cells | 5 | 2023 | 634 | 0.290 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2024 | 1784 | 0.280 |
Why?
|
| Lymph Node Excision | 4 | 2024 | 1269 | 0.280 |
Why?
|
| Odds Ratio | 7 | 2020 | 9644 | 0.280 |
Why?
|
| Proportional Hazards Models | 11 | 2024 | 12448 | 0.280 |
Why?
|
| Longitudinal Studies | 12 | 2022 | 14599 | 0.280 |
Why?
|
| Feasibility Studies | 6 | 2019 | 5239 | 0.280 |
Why?
|
| Dyspnea | 2 | 2012 | 1347 | 0.280 |
Why?
|
| Survival Analysis | 12 | 2024 | 10072 | 0.270 |
Why?
|
| Health Behavior | 3 | 2022 | 2643 | 0.270 |
Why?
|
| Estrogen Receptor alpha | 2 | 2021 | 583 | 0.270 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2024 | 4575 | 0.270 |
Why?
|
| Program Development | 1 | 2012 | 1293 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3245 | 0.270 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 940 | 0.270 |
Why?
|
| Neoplasm Metastasis | 11 | 2021 | 4910 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 5671 | 0.260 |
Why?
|
| Women's Health | 2 | 2015 | 2066 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2024 | 561 | 0.250 |
Why?
|
| Placebos | 3 | 2021 | 1667 | 0.250 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2021 | 943 | 0.250 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 2048 | 0.240 |
Why?
|
| Palliative Care | 2 | 2024 | 3593 | 0.240 |
Why?
|
| Patients | 3 | 2011 | 906 | 0.240 |
Why?
|
| Genomics | 4 | 2024 | 5822 | 0.240 |
Why?
|
| Ovarian Neoplasms | 3 | 2018 | 4849 | 0.240 |
Why?
|
| Consensus | 6 | 2024 | 3117 | 0.240 |
Why?
|
| Disease Management | 7 | 2018 | 2506 | 0.240 |
Why?
|
| Physical Fitness | 4 | 2017 | 743 | 0.240 |
Why?
|
| Lymphatic Metastasis | 5 | 2021 | 2913 | 0.230 |
Why?
|
| Mental Health | 1 | 2019 | 3253 | 0.230 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 26065 | 0.230 |
Why?
|
| Cisplatin | 3 | 2020 | 1650 | 0.230 |
Why?
|
| Anthracyclines | 3 | 2021 | 285 | 0.230 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2024 | 496 | 0.230 |
Why?
|
| Directive Counseling | 2 | 2015 | 170 | 0.220 |
Why?
|
| Heart | 2 | 2016 | 4403 | 0.220 |
Why?
|
| Life Style | 6 | 2023 | 3907 | 0.220 |
Why?
|
| Mutation | 12 | 2023 | 30015 | 0.220 |
Why?
|
| Family | 3 | 2023 | 3193 | 0.220 |
Why?
|
| Age of Onset | 4 | 2016 | 3303 | 0.220 |
Why?
|
| Confidence Intervals | 4 | 2020 | 2925 | 0.220 |
Why?
|
| Incidence | 8 | 2024 | 21339 | 0.220 |
Why?
|
| Data Collection | 6 | 2013 | 3316 | 0.220 |
Why?
|
| Early Detection of Cancer | 6 | 2019 | 3196 | 0.210 |
Why?
|
| North America | 2 | 2024 | 1273 | 0.210 |
Why?
|
| Cost of Illness | 3 | 2024 | 1937 | 0.210 |
Why?
|
| Registries | 5 | 2019 | 8209 | 0.210 |
Why?
|
| Research Support as Topic | 1 | 2007 | 697 | 0.210 |
Why?
|
| Lymph Nodes | 4 | 2023 | 3461 | 0.200 |
Why?
|
| Age Distribution | 2 | 2020 | 2872 | 0.200 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2021 | 407 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 3 | 2022 | 990 | 0.200 |
Why?
|
| Body Weight | 4 | 2022 | 4615 | 0.200 |
Why?
|
| Heterozygote | 3 | 2024 | 2780 | 0.200 |
Why?
|
| Androstadienes | 1 | 2024 | 348 | 0.200 |
Why?
|
| Retrospective Studies | 25 | 2024 | 80583 | 0.200 |
Why?
|
| Treatment Refusal | 2 | 2018 | 429 | 0.200 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2023 | 117 | 0.200 |
Why?
|
| Ethics, Clinical | 1 | 2002 | 101 | 0.190 |
Why?
|
| Mass Screening | 5 | 2014 | 5425 | 0.190 |
Why?
|
| Fear | 3 | 2021 | 1477 | 0.190 |
Why?
|
| Male | 49 | 2024 | 360402 | 0.190 |
Why?
|
| Cancer Care Facilities | 3 | 2016 | 422 | 0.190 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2013 | 107 | 0.190 |
Why?
|
| Pilot Projects | 10 | 2019 | 8619 | 0.190 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 144 | 0.190 |
Why?
|
| Resource Allocation | 2 | 2013 | 350 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2024 | 350 | 0.180 |
Why?
|
| Mammaplasty | 4 | 2021 | 1232 | 0.180 |
Why?
|
| Maytansine | 1 | 2021 | 86 | 0.180 |
Why?
|
| Population Surveillance | 4 | 2019 | 2597 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 1582 | 0.180 |
Why?
|
| Evidence-Based Medicine | 7 | 2021 | 3680 | 0.180 |
Why?
|
| Camptothecin | 1 | 2024 | 591 | 0.180 |
Why?
|
| Temperance | 1 | 2020 | 87 | 0.180 |
Why?
|
| Taxoids | 2 | 2022 | 667 | 0.180 |
Why?
|
| Drug Industry | 1 | 2007 | 788 | 0.180 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 12043 | 0.180 |
Why?
|
| Patient-Centered Care | 3 | 2023 | 1419 | 0.180 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2023 | 732 | 0.170 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2019 | 709 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 1700 | 0.170 |
Why?
|
| Self Report | 4 | 2016 | 3727 | 0.170 |
Why?
|
| Publishing | 1 | 2007 | 832 | 0.170 |
Why?
|
| Ketones | 1 | 2020 | 183 | 0.170 |
Why?
|
| Furans | 1 | 2020 | 202 | 0.160 |
Why?
|
| SEER Program | 2 | 2021 | 1450 | 0.160 |
Why?
|
| Switzerland | 4 | 2022 | 318 | 0.160 |
Why?
|
| Child | 15 | 2024 | 80089 | 0.160 |
Why?
|
| Doxorubicin | 6 | 2019 | 2224 | 0.160 |
Why?
|
| Methotrexate | 5 | 2019 | 1716 | 0.160 |
Why?
|
| Weight Loss | 5 | 2022 | 2682 | 0.160 |
Why?
|
| Truth Disclosure | 1 | 2003 | 432 | 0.160 |
Why?
|
| Recurrence | 5 | 2019 | 8426 | 0.160 |
Why?
|
| Internet | 5 | 2021 | 3094 | 0.150 |
Why?
|
| Vaginal Diseases | 1 | 2019 | 103 | 0.150 |
Why?
|
| Leukemia | 2 | 2023 | 1520 | 0.150 |
Why?
|
| Genetic Counseling | 2 | 2014 | 627 | 0.150 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 13383 | 0.150 |
Why?
|
| Female Urogenital Diseases | 1 | 2018 | 57 | 0.150 |
Why?
|
| Societies, Medical | 5 | 2018 | 3901 | 0.150 |
Why?
|
| Double-Blind Method | 4 | 2024 | 12333 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 3705 | 0.140 |
Why?
|
| Decision Support Techniques | 4 | 2020 | 1999 | 0.140 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2019 | 147 | 0.140 |
Why?
|
| Prevalence | 5 | 2024 | 15702 | 0.140 |
Why?
|
| Unemployment | 1 | 2019 | 210 | 0.140 |
Why?
|
| Axilla | 4 | 2023 | 624 | 0.140 |
Why?
|
| Epothilones | 2 | 2021 | 42 | 0.140 |
Why?
|
| Leuprolide | 1 | 2019 | 312 | 0.140 |
Why?
|
| Counseling | 3 | 2020 | 1538 | 0.140 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 1923 | 0.140 |
Why?
|
| Lactation | 1 | 2019 | 397 | 0.140 |
Why?
|
| Menstrual Cycle | 2 | 2011 | 539 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 1725 | 0.140 |
Why?
|
| Risk | 7 | 2024 | 9603 | 0.140 |
Why?
|
| Immunoconjugates | 1 | 2024 | 951 | 0.140 |
Why?
|
| Factor Analysis, Statistical | 1 | 2019 | 997 | 0.130 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2016 | 94 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 620 | 0.130 |
Why?
|
| Lung | 2 | 2012 | 9999 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 9171 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2023 | 26183 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 678 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2024 | 1723 | 0.130 |
Why?
|
| Telemedicine | 3 | 2022 | 3051 | 0.130 |
Why?
|
| Social Class | 2 | 2018 | 1993 | 0.130 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 376 | 0.120 |
Why?
|
| Community Health Centers | 1 | 2019 | 460 | 0.120 |
Why?
|
| Massachusetts | 4 | 2014 | 8835 | 0.120 |
Why?
|
| Libido | 1 | 2015 | 124 | 0.120 |
Why?
|
| Acupuncture Therapy | 1 | 2019 | 486 | 0.120 |
Why?
|
| Psychotherapy, Brief | 1 | 2016 | 118 | 0.120 |
Why?
|
| Sweating | 1 | 2015 | 155 | 0.120 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 4802 | 0.120 |
Why?
|
| Nurses | 1 | 2004 | 2477 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 2270 | 0.110 |
Why?
|
| Patient Care Team | 3 | 2014 | 2515 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 3593 | 0.110 |
Why?
|
| Videoconferencing | 1 | 2016 | 203 | 0.110 |
Why?
|
| Estradiol | 2 | 2013 | 1937 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 1365 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 9417 | 0.110 |
Why?
|
| Colorado | 1 | 2014 | 165 | 0.110 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2003 | 2152 | 0.110 |
Why?
|
| Models, Psychological | 1 | 2018 | 829 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2015 | 6016 | 0.110 |
Why?
|
| Health Status Disparities | 2 | 2015 | 1846 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2000 | 815 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2022 | 629 | 0.110 |
Why?
|
| Cause of Death | 3 | 2024 | 3683 | 0.110 |
Why?
|
| Spirituality | 1 | 2018 | 430 | 0.110 |
Why?
|
| Embryo Transfer | 1 | 2017 | 522 | 0.110 |
Why?
|
| Echocardiography | 3 | 2016 | 4987 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2023 | 1580 | 0.100 |
Why?
|
| Menarche | 2 | 2013 | 532 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 1378 | 0.100 |
Why?
|
| Aspirin | 1 | 2024 | 3127 | 0.100 |
Why?
|
| Sarcoma | 1 | 2023 | 1800 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 2916 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2022 | 4677 | 0.100 |
Why?
|
| Europe | 4 | 2022 | 3415 | 0.100 |
Why?
|
| American Cancer Society | 1 | 2012 | 69 | 0.100 |
Why?
|
| Psychotherapy, Group | 1 | 2016 | 413 | 0.100 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2015 | 284 | 0.100 |
Why?
|
| Canada | 2 | 2024 | 2120 | 0.100 |
Why?
|
| Heart Ventricles | 2 | 2016 | 3796 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2018 | 1208 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2024 | 5109 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2018 | 563 | 0.100 |
Why?
|
| Prejudice | 1 | 2015 | 571 | 0.100 |
Why?
|
| Self Care | 2 | 2013 | 796 | 0.100 |
Why?
|
| Environment Design | 1 | 2013 | 173 | 0.090 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 3351 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2003 | 3567 | 0.090 |
Why?
|
| Developing Countries | 2 | 2013 | 2868 | 0.090 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2010 | 16 | 0.090 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 442 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2021 | 2008 | 0.090 |
Why?
|
| Mandatory Testing | 1 | 2010 | 23 | 0.090 |
Why?
|
| Inservice Training | 1 | 2013 | 375 | 0.090 |
Why?
|
| Benzothiazoles | 1 | 2011 | 247 | 0.090 |
Why?
|
| Micro-Electrical-Mechanical Systems | 1 | 2010 | 30 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2012 | 1835 | 0.090 |
Why?
|
| Cyclohexanols | 1 | 2010 | 126 | 0.090 |
Why?
|
| Pain | 2 | 2022 | 5062 | 0.090 |
Why?
|
| Anthropometry | 2 | 2012 | 1338 | 0.090 |
Why?
|
| Premature Birth | 1 | 2022 | 1782 | 0.090 |
Why?
|
| Health Care Surveys | 1 | 2017 | 2422 | 0.090 |
Why?
|
| Research Report | 1 | 2012 | 367 | 0.080 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 15250 | 0.080 |
Why?
|
| Diet | 1 | 2007 | 8049 | 0.080 |
Why?
|
| Long-Term Care | 1 | 2013 | 631 | 0.080 |
Why?
|
| Weight Gain | 4 | 2022 | 2349 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 2020 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 10754 | 0.080 |
Why?
|
| Italy | 2 | 2022 | 842 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1745 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2020 | 2056 | 0.080 |
Why?
|
| Medical Records | 2 | 2009 | 1408 | 0.080 |
Why?
|
| Informed Consent | 1 | 2015 | 1007 | 0.080 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2009 | 131 | 0.080 |
Why?
|
| Inhibins | 1 | 2009 | 210 | 0.080 |
Why?
|
| Disease Progression | 3 | 2024 | 13495 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 2756 | 0.080 |
Why?
|
| Disabled Persons | 2 | 1997 | 1226 | 0.080 |
Why?
|
| Embryo Culture Techniques | 1 | 2009 | 84 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 1110 | 0.080 |
Why?
|
| Vaginitis | 1 | 2008 | 49 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2000 | 2518 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2016 | 2481 | 0.080 |
Why?
|
| Penetrance | 2 | 2022 | 382 | 0.070 |
Why?
|
| Personal Satisfaction | 1 | 2012 | 645 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3743 | 0.070 |
Why?
|
| Genistein | 1 | 2007 | 86 | 0.070 |
Why?
|
| Inflammation | 2 | 2024 | 10759 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 12966 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6473 | 0.070 |
Why?
|
| Advance Directives | 1 | 2009 | 249 | 0.070 |
Why?
|
| Melanoma | 2 | 2023 | 5696 | 0.070 |
Why?
|
| Medicaid | 3 | 2012 | 2814 | 0.070 |
Why?
|
| Reproduction | 1 | 2012 | 646 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2010 | 960 | 0.070 |
Why?
|
| Heart Rate | 1 | 2018 | 4181 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2012 | 802 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2015 | 629 | 0.070 |
Why?
|
| Lignans | 1 | 2007 | 84 | 0.070 |
Why?
|
| Isoflavones | 1 | 2007 | 136 | 0.070 |
Why?
|
| Genotype | 4 | 2019 | 12977 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3599 | 0.070 |
Why?
|
| Postmenopause | 2 | 2024 | 2511 | 0.070 |
Why?
|
| Emotions | 2 | 2015 | 2741 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 1394 | 0.070 |
Why?
|
| Radiotherapy | 3 | 2017 | 1497 | 0.070 |
Why?
|
| Arousal | 1 | 2012 | 1171 | 0.070 |
Why?
|
| Health Surveys | 2 | 2013 | 4036 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 5334 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2007 | 641 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 15829 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 15908 | 0.060 |
Why?
|
| Research | 1 | 2014 | 1977 | 0.060 |
Why?
|
| Fertility Agents | 1 | 2005 | 11 | 0.060 |
Why?
|
| Advisory Committees | 1 | 2009 | 787 | 0.060 |
Why?
|
| Physical Endurance | 1 | 2008 | 366 | 0.060 |
Why?
|
| Mexico | 2 | 2018 | 757 | 0.060 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2006 | 242 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2021 | 22153 | 0.060 |
Why?
|
| Drug Utilization | 2 | 2002 | 1186 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2851 | 0.060 |
Why?
|
| Thinking | 2 | 2021 | 319 | 0.060 |
Why?
|
| Professional Practice | 1 | 2007 | 313 | 0.060 |
Why?
|
| Internationality | 2 | 2024 | 1000 | 0.060 |
Why?
|
| Reproductive Medicine | 1 | 2006 | 99 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2012 | 1528 | 0.060 |
Why?
|
| Osteoporosis | 1 | 2014 | 1604 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2015 | 1937 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2015 | 2495 | 0.060 |
Why?
|
| Syndrome | 2 | 2022 | 3268 | 0.060 |
Why?
|
| Salpingectomy | 1 | 2024 | 44 | 0.060 |
Why?
|
| Neoplastic Processes | 1 | 2023 | 35 | 0.060 |
Why?
|
| Medication Errors | 1 | 2010 | 783 | 0.060 |
Why?
|
| Authorship | 1 | 2007 | 284 | 0.060 |
Why?
|
| Nurse-Patient Relations | 1 | 2004 | 99 | 0.060 |
Why?
|
| Neutropenia | 2 | 2006 | 885 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2012 | 2242 | 0.060 |
Why?
|
| Muscle Strength | 1 | 2008 | 624 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2016 | 4937 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2015 | 6339 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 3873 | 0.050 |
Why?
|
| Biopsy | 2 | 2017 | 6763 | 0.050 |
Why?
|
| Smoking | 3 | 2020 | 9054 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2014 | 3196 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 12661 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 1927 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8542 | 0.050 |
Why?
|
| Telephone | 2 | 2020 | 626 | 0.050 |
Why?
|
| Phenotype | 1 | 2020 | 16572 | 0.050 |
Why?
|
| New Jersey | 1 | 2003 | 295 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 1178 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 2164 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2021 | 3410 | 0.050 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2021 | 69 | 0.050 |
Why?
|
| Exercise Test | 2 | 2020 | 2127 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 627 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 42193 | 0.050 |
Why?
|
| Patient Rights | 1 | 2002 | 125 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2014 | 2778 | 0.050 |
Why?
|
| Sex Factors | 1 | 2015 | 10549 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2017 | 4642 | 0.050 |
Why?
|
| Hospitalization | 1 | 2021 | 10708 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2005 | 719 | 0.050 |
Why?
|
| Body Composition | 3 | 2017 | 2426 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4309 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2019 | 15609 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 3611 | 0.050 |
Why?
|
| Phthalazines | 1 | 2023 | 383 | 0.040 |
Why?
|
| Purines | 1 | 2024 | 606 | 0.040 |
Why?
|
| Comorbidity | 2 | 2019 | 10507 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 69 | 0.040 |
Why?
|
| Latin America | 1 | 2021 | 407 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 36401 | 0.040 |
Why?
|
| Heart Failure | 2 | 2024 | 11670 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 799 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2024 | 573 | 0.040 |
Why?
|
| Linear Models | 1 | 2010 | 5866 | 0.040 |
Why?
|
| Cotinine | 1 | 2020 | 206 | 0.040 |
Why?
|
| Vinblastine | 1 | 2001 | 488 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2012 | 3735 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2012 | 20556 | 0.040 |
Why?
|
| Choice Behavior | 2 | 2019 | 825 | 0.040 |
Why?
|
| Contraception | 1 | 2022 | 347 | 0.040 |
Why?
|
| Motivation | 1 | 2009 | 2003 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 4028 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2022 | 603 | 0.040 |
Why?
|
| Arthralgia | 1 | 2022 | 461 | 0.040 |
Why?
|
| Bupropion | 1 | 2020 | 304 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 677 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 2214 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 1669 | 0.040 |
Why?
|
| Cognition Disorders | 2 | 2004 | 3979 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 2568 | 0.040 |
Why?
|
| Vulva | 1 | 2018 | 84 | 0.040 |
Why?
|
| Arm | 1 | 2021 | 588 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 899 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2019 | 504 | 0.040 |
Why?
|
| France | 1 | 2019 | 492 | 0.040 |
Why?
|
| Vacuum | 1 | 2017 | 65 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2011 | 5965 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 1997 | 1835 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2018 | 247 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 6345 | 0.040 |
Why?
|
| Interdisciplinary Communication | 2 | 2013 | 928 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 206 | 0.040 |
Why?
|
| Focus Groups | 2 | 2017 | 1409 | 0.030 |
Why?
|
| Uncertainty | 1 | 2022 | 752 | 0.030 |
Why?
|
| Weaning | 1 | 2016 | 103 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2018 | 350 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 20077 | 0.030 |
Why?
|
| Work | 1 | 1997 | 195 | 0.030 |
Why?
|
| Filgrastim | 2 | 2006 | 132 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 888 | 0.030 |
Why?
|
| Cell Count | 1 | 2020 | 1834 | 0.030 |
Why?
|
| Anemia | 1 | 2005 | 1504 | 0.030 |
Why?
|
| Saliva | 1 | 2020 | 828 | 0.030 |
Why?
|
| Ireland | 1 | 2016 | 170 | 0.030 |
Why?
|
| Morbidity | 1 | 2021 | 1750 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2020 | 709 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 167 | 0.030 |
Why?
|
| Creatinine | 1 | 2020 | 1895 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2021 | 597 | 0.030 |
Why?
|
| Nausea | 1 | 2018 | 679 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2019 | 491 | 0.030 |
Why?
|
| Necrosis | 1 | 2019 | 1610 | 0.030 |
Why?
|
| Body Height | 1 | 2021 | 1565 | 0.030 |
Why?
|
| Vomiting | 1 | 2018 | 651 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2546 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2018 | 518 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 2079 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2016 | 210 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2024 | 2057 | 0.030 |
Why?
|
| Methylene Blue | 1 | 2014 | 155 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2016 | 471 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2017 | 846 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 532 | 0.030 |
Why?
|
| Insulin | 1 | 2008 | 6593 | 0.030 |
Why?
|
| Atrophy | 1 | 2018 | 1632 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2016 | 421 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2010 | 0.030 |
Why?
|
| Demography | 1 | 1997 | 1643 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 1894 | 0.030 |
Why?
|
| Vagina | 1 | 2018 | 841 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 1185 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2021 | 6223 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 2174 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2013 | 245 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 1737 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 123 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 2803 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 1999 | 757 | 0.020 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 15498 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 737 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2014 | 562 | 0.020 |
Why?
|
| Uterine Hemorrhage | 1 | 2013 | 240 | 0.020 |
Why?
|
| California | 1 | 2015 | 1431 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 1768 | 0.020 |
Why?
|
| Schools | 1 | 2020 | 1483 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2013 | 553 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 2112 | 0.020 |
Why?
|
| Social Security | 1 | 1991 | 101 | 0.020 |
Why?
|
| Nomograms | 1 | 2012 | 230 | 0.020 |
Why?
|
| Quality of Health Care | 2 | 2017 | 4325 | 0.020 |
Why?
|
| International Cooperation | 1 | 2017 | 1422 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 397 | 0.020 |
Why?
|
| Polyethylene Glycols | 2 | 2006 | 1182 | 0.020 |
Why?
|
| Infertility, Male | 1 | 2013 | 396 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2017 | 1242 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4570 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2016 | 1178 | 0.020 |
Why?
|
| Health Personnel | 2 | 2013 | 3333 | 0.020 |
Why?
|
| Grief | 1 | 2012 | 254 | 0.020 |
Why?
|
| Pregnancy Complications | 2 | 2020 | 2948 | 0.020 |
Why?
|
| Economics | 1 | 2010 | 141 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 617 | 0.020 |
Why?
|
| Infant | 2 | 2022 | 36157 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3027 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4919 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2011 | 246 | 0.020 |
Why?
|
| Marital Status | 1 | 2010 | 425 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 18220 | 0.020 |
Why?
|
| Alleles | 1 | 2019 | 6861 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2008 | 150 | 0.020 |
Why?
|
| Community Health Services | 1 | 2012 | 654 | 0.020 |
Why?
|
| Prescriptions | 1 | 2010 | 386 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 5672 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 590 | 0.020 |
Why?
|
| Lymphedema | 1 | 2013 | 523 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 934 | 0.020 |
Why?
|
| Curriculum | 1 | 2020 | 3739 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1896 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2008 | 518 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2017 | 2768 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2010 | 494 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 883 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2006 | 6520 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 1459 | 0.020 |
Why?
|
| Animals | 4 | 2016 | 168202 | 0.020 |
Why?
|
| Gonads | 1 | 2006 | 109 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1924 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 5304 | 0.020 |
Why?
|
| Locomotion | 1 | 1988 | 388 | 0.020 |
Why?
|
| Social Values | 1 | 2006 | 225 | 0.020 |
Why?
|
| Semen Preservation | 1 | 2005 | 35 | 0.020 |
Why?
|
| Goals | 1 | 2011 | 708 | 0.020 |
Why?
|
| Pharmaceutical Services | 1 | 2007 | 141 | 0.020 |
Why?
|
| Cognition | 1 | 2023 | 6988 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2332 | 0.020 |
Why?
|
| Antiemetics | 1 | 2006 | 186 | 0.020 |
Why?
|
| Internal-External Control | 1 | 2006 | 358 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 9586 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 1027 | 0.010 |
Why?
|
| Rheumatic Diseases | 1 | 1991 | 649 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2019 | 6561 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 3868 | 0.010 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 4764 | 0.010 |
Why?
|
| Activities of Daily Living | 2 | 1991 | 2419 | 0.010 |
Why?
|
| Psychometrics | 1 | 2012 | 3062 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1986 | 418 | 0.010 |
Why?
|
| Rheumatology | 2 | 2003 | 615 | 0.010 |
Why?
|
| Prednisone | 1 | 2006 | 1562 | 0.010 |
Why?
|
| Testis | 1 | 2005 | 792 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2000 | 5144 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2017 | 3801 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 1986 | 552 | 0.010 |
Why?
|
| Safety Management | 1 | 2007 | 760 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 568 | 0.010 |
Why?
|
| Rats | 1 | 2016 | 23716 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6305 | 0.010 |
Why?
|
| Health Policy | 1 | 2012 | 2682 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 16968 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2006 | 1252 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 983 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2006 | 1946 | 0.010 |
Why?
|
| Home Care Services | 1 | 1986 | 648 | 0.010 |
Why?
|
| Histamine H1 Antagonists | 1 | 1999 | 100 | 0.010 |
Why?
|
| Fever | 1 | 2006 | 1618 | 0.010 |
Why?
|
| Algorithms | 2 | 2012 | 14024 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1189 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1999 | 346 | 0.010 |
Why?
|
| Terminal Care | 1 | 2009 | 1755 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 1810 | 0.010 |
Why?
|
| Epinephrine | 1 | 1999 | 792 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5430 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2000 | 2112 | 0.010 |
Why?
|
| Medicare | 1 | 2012 | 6774 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 23415 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2008 | 6390 | 0.010 |
Why?
|
| Boston | 1 | 2005 | 9313 | 0.010 |
Why?
|
| Occupations | 1 | 1995 | 516 | 0.010 |
Why?
|
| Education | 1 | 1995 | 534 | 0.010 |
Why?
|
| Work Capacity Evaluation | 1 | 1991 | 42 | 0.010 |
Why?
|
| Food Hypersensitivity | 1 | 1999 | 726 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 81368 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 1948 | 0.010 |
Why?
|
| Self-Help Devices | 1 | 1988 | 62 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 14649 | 0.000 |
Why?
|
| Osteoarthritis | 1 | 1991 | 1063 | 0.000 |
Why?
|
| Costs and Cost Analysis | 1 | 1986 | 1663 | 0.000 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1991 | 3752 | 0.000 |
Why?
|